SAN DIEGO--(BUSINESS WIRE)--Feb. 1, 2006--Immusol announced today that it has entered into a license agreement with Baylor College of Medicine for the exclusive, worldwide rights to a novel oncolytic viral therapy using herpes simplex viruses. Baylor researchers have developed extensive expertise in the field of oncolytic virotherapies against a wide variety of solid tumors. The in-licensed therapy represents Baylor’s most advanced virotherapy to date and has shown safety and strong efficacy in a number of preclinical animal tumor models. The financial terms of the license agreement were not disclosed.
